Akeso doses first patient in Phase II trial of AK146D1 ADC plus ivonescimab in advanced breast cancer

• Akeso dosed the first patient in a Phase II study of TROP2/Nectin-4 bispecific ADC AK146D1 combined with ivonescimab in advanced breast cancer.
• Results have not been presented; the trial will assess whether the regimen can improve outcomes while keeping safety manageable.
• Focus includes first-line HR+/HER2- disease, also triple-negative breast cancer, a strategic push for its IO2.0 and ADC2.0 combination approach.
• Ivonescimab has shown favorable results versus PD-1-based regimens in prior Phase III studies; AK146D1 showed encouraging early activity and tolerability.
• A Phase III ivonescimab-based combination study in first-line triple-negative breast cancer is ongoing, extending the same breast cancer strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608100005PR_NEWS_USPR_____CN22425) on August 10, 2026, and is solely responsible for the information contained therein.